This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023736%3A_____%2F09%3A00008561%21RIV10-MZ0-00023736/
dctermshttp://purl.org/dc/terms/
n16http://purl.org/net/nknouf/ns/bibtex#
n20http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/ontology/domain/vavai/
n11https://schema.org/
n9http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023736%3A_____%2F09%3A00008561%21RIV10-MZ0-00023736
rdf:type
n7:Vysledek skos:Concept
dcterms:description
Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow
dcterms:title
Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma
skos:prefLabel
Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma
skos:notation
RIV/00023736:_____/09:00008561!RIV10-MZ0-00023736
n3:aktivita
n17:Z n17:P
n3:aktivity
P(LC06044), Z(MZ0UHKT2005)
n3:dodaniDat
n15:2010
n3:domaciTvurceVysledku
n20:7991401
n3:druhVysledku
n4:C
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
337252
n3:idVysledku
RIV/00023736:_____/09:00008561
n3:jazykVysledku
n19:eng
n3:klicovaSlova
multiple myeloma; proteasome; proteasome inhibitor bortezomib; apoptosis
n3:klicoveSlovo
n8:apoptosis n8:proteasome%20inhibitor%20bortezomib n8:proteasome n8:multiple%20myeloma
n3:kontrolniKodProRIV
[D4F92B23CA96]
n3:mistoVydani
New York
n3:nazevZdroje
Multiple myeloma : symptoms, diagnosis and treatment
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetStranKnihy
265
n3:pocetTvurcuVysledku
1
n3:projekt
n6:LC06044
n3:rokUplatneniVysledku
n15:2009
n3:tvurceVysledku
Fuchs, Ota
n3:zamer
n9:MZ0UHKT2005
s:numberOfPages
48
n16:hasPublisher
Nova Science Publishers
n11:isbn
978-1-60876-108-1